CLAIMS

1. A recombinant adenovirus (Ad) comprising (a) Ad capsid polypeptides from a human Ad6 strain and (b) at least two hexon hypervariable region (HVR) polypeptides from a human Ad57 strain, said recombinant Ad further comprising nucleic acids which encode 4-1BBL, CD40L or a combination of 4-1BBL and CD40L.

2. A recombinant adenovirus (Ad) comprising (a) Ad capsid polypeptides from a human Ad6 strain and (b) at least two hexon hypervariable region (HVR) polypeptides from a human Ad57 strain, wherein the recombinant Ad is a conditionally-replicating Ad (CRAd), said CRAd further comprising nucleic acids which encode 4-1BBL, CD40L or a combination of 4-1BBL and CD40L.

3. The recombinant Ad of claims 1 or 2, wherein the capsid hexon polypeptides of the human Ad6 strain comprise capsid hexon hypervariable region (HVR) polypeptides 1-7 from the human Ad57 strain.

4. The recombinant Ad of claims 1 or 2, wherein the capsid hexon polypeptides of the human Ad6 strain comprise capsid hexon hypervariable region (HVR) polypeptides 2-6 from the human Ad57 strain.

5. The recombinant Ad of any one of claims 1-4, further comprising a capsid polypeptide from one or more different Ad strains, wherein the capsid polypeptide is a fiber polypeptide which is different from a fiber polypeptide of the human Ad6 and human Ad57 strains.

6. The recombinant Ad of any one of claims 1-5, further comprising amino acid substitutions and/or amino acid modifications, wherein the amino acid substitution is to a cysteine in HVR polypeptides and the amino acid modification is selected from PEGylation and BAPylation of a cysteine in the HVR polypeptide.

7. The recombinant Ad of claim 2 comprising an amino acid sequence of SEQ ID NO:43, SEQ ID NO:44 or SEQ ID NO:45.

8. A recombinant adenovirus (Ad) comprising (a) an Ad genome encoding hexon polypeptides from a human Ad6 strain and (b) nucleic acids encoding at least two hexon hypervariable region (HVR) polypeptides from a human Ad57 strain, said recombinant Ad further comprising nucleic acids which encode 4-1BBL, CD40L or a combination of 4-1BBL and CD40L.

9. A recombinant adenovirus (Ad) comprising (a) an Ad genome encoding hexon polypeptides from a human Ad6 strain and (b) nucleic acids encoding at least two hexon hypervariable region (HVR) polypeptides from a human Ad57 strain, wherein the recombinant Ad is a conditionally-replicating Ad (CRAd), said CRAd further comprising nucleic acids which encode 4-1BBL, CD40L or a combination of 4-1BBL and CD40L.

10. The recombinant Ad of claims 8 or 9, wherein the capsid hexon polypeptides of the human Ad6 strain comprise capsid hexon hypervariable region (HVR) polypeptides 1-7 from the human Ad57 strain.

11. The recombinant Ad of claims 8 or 9, wherein the capsid hexon polypeptides of the human Ad6 strain comprise capsid hexon hypervariable region (HVR) polypeptides 2-6 from the human Ad57 strain.

12. The recombinant Ad of any one of claims 8-10, further comprising nucleic acids encoding a capsid polypeptide from one or more different Ad strains, wherein the capsid polypeptide is a fiber polypeptide which is different from a fiber polypeptide of the human Ad6 and human Ad57 strains.

13. The recombinant Ad of claim 9, which is modified to comprise a dl1101 deletion in nucleic acids encoding an E1 polypeptide, modified to comprise a dl1107 deletion in nucleic acids encoding an E1 polypeptide, or modified to comprise a dl1101 deletion and a dl1107 deletion in nucleic acids encoding an E1 polypeptide.

14. The recombinant Ad of claim 13 comprising a nucleic acid encoding an amino acid sequence of SEQ ID NO:43, SEQ ID NO:44 or SEQ ID NO:45.

15. Use of a recombinant adenovirus (Ad) of any one of claims 1-14, in the manufacture of a pharmaceutical composition for the treatment of cancer in a mammal, wherein said pharmaceutical composition is to be administered to said mammal.

16. The use according to claim 15, wherein said cancer is selected from the group consisting of prostate cancer, ovarian cancer, lung cancer, hepatocellular carcinoma, pancreatic cancer, kidney cancer, melanoma, brain cancer, colon cancer, lymphoma, myeloma, lymphocytic leukemia, and myelogenous leukemia.

17. The use according to any one of claims 15-16, wherein said pharmaceutical composition is to be administered systematically.

18. The use according to claim 17, wherein said pharmaceutical composition is to be administered intramuscularly, intranasally, or intravenously.

19. The use according to any one of claims 15-16, wherein said pharmaceutical composition is to be administered locally.

20. The use according to claim 19, wherein said pharmaceutical composition is to be injected intratumorally.

21. A pharmaceutical composition comprising a recombinant adenovirus (Ad) of any one of claims 1-14, for use in the treatment of cancer.